Non-secretory myeloma: a clinician's guide.

Area of Science:

• Hematology
• Oncology
• Plasma Cell Disorders

Background:

• Multiple myeloma treatment has advanced significantly in the last decade.
• Non-secretory myeloma (NSM) presents unique challenges in treatment and response assessment.
• The serum free light chain assay has redefined NSM, identifying it in <3% of new cases.

Purpose of the Study:

• To review the current understanding and management of non-secretory multiple myeloma.
• To explore advancements in disease assessment and prognosis for NSM patients.
• To highlight future directions in response evaluation for multiple myeloma.

Main Methods:

• Review of current literature on multiple myeloma, focusing on NSM.
• Analysis of diagnostic advancements, including serum free light chain assay.
• Evaluation of emerging response assessment techniques like PET/CT and MRD.

Main Results:

• The incidence of truly non-secretory myeloma is now less than 3% due to improved diagnostics.
• Prognosis for NSM patients appears similar to or better than for secretory myeloma.
• Positron emission tomography (PET)/CT scans and minimal residual disease (MRD) assessment show promise for response evaluation.

Conclusions:

• Non-secretory myeloma is a rare subtype with a generally favorable prognosis.
• Advanced imaging and MRD assessment are crucial for future response evaluation in NSM.
• Combined imaging and MRD strategies may improve assessment for all myeloma patients.